Previous 10 | Next 10 |
Ten Years Running: FORTUNE Names Quest Diagnostics one of 2024 "World's Most Admired Companies" PR Newswire SECAUCUS, N.J. , Jan. 31, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today annou...
2024-01-31 11:22:20 ET More on Quest Diagnostics Quest Diagnostics: Market Overreaction Creates Investment Opportunity Quest, FitBit team up to evaluate wearables for metabolic health Quest, Ultima Genomics team up on MRD test development Seeking Alpha’...
2024-01-30 11:52:28 ET Summary Investors saw some nice dividend increases from dividend growth companies in January, including 10%+ boosts from ADM, Fastenal, and Franklin Electric. A boatload of companies are announcing annual increases in February. Twenty companies are on tap fo...
Study to evaluate how behavioral and sensor data from wearables and blood tests can be leveraged to help individuals better assess and manage their metabolic health SECAUCUS, NJ / ACCESSWIRE / January 29, 2024 / Fitbit and Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnos...
2024-01-28 11:23:20 ET Summary A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. Introduction The D...
2024-01-26 16:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Haystack Oncology, developer of Haystack MRD™, and TriSalus Life Sciences collaborate in connection with the clinical development of TriSalus' TLR9 agonist in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma PR Newswire BALTIMOR...
2024-01-18 05:04:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Blood tests for dozens of types of cancer have been invented. These tests, known as liquid biopsies, could save tens of millions of lives. That’s because there’s currently no good...
2024-01-17 12:22:09 ET More on Quest Diagnostics Quest Diagnostics: Market Overreaction Creates Investment Opportunity Quest Diagnostics: Moving Past Covid Quest Diagnostics Inc. (DGX) Q3 2023 Earnings Call Transcript Quest, Ultima Genomics team up on MRD tes...
Quest Diagnostics to Release Fourth Quarter and Full Year 2023 Financial Results on February 1, 2024 PR Newswire SECAUCUS, N.J. , Jan. 17, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic information ser...
News, Short Squeeze, Breakout and More Instantly...
Quest Diagnostics Incorporated Company Name:
DGX Stock Symbol:
NYSE Market:
Quest Diagnostics Incorporated Website:
Haystack Oncology and Université de Montréal's affiliated hospital research centre, the CRCHUM, to Deploy Haystack MRD™ Technology in Research Study for Metastatic Colorectal Cancer PR Newswire BALTIMORE, Md. and MONTREAL , July 29, 2024 /PRN...
BD, Quest Diagnostics Join Forces to Develop Companion Diagnostics for Cancer, Other Diseases PR Newswire Collaboration on Flow Cytometry-Based Companion Diagnostics to Advance Personalized Health Care FRANKLIN LAKES, N.J. and SECAUCUS, N.J. , July 25, 20...
2024-07-24 07:00:10 ET Eric Coldwell from Robert W. Baird issued a price target of $154.00 for DGX on 2024-07-24 06:36:00. The adjusted price target was set to $154.00. At the time of the announcement, DGX was trading at $140.96. The overall price target consensus is at ...